Combined detection of circulating tumor cells, α-fetoprotein heterogene-3 and α-fetoprotein in the early diagnosis of HCC for the prediction of efficacy, prognosis, recurrence after microwave ablation
Abstract Background Early diagnosis can significantly improve treatment outcomes for hepatocellular carcinoma (HCC) patients. Currently, the dosage of serum alpha fetoprotein (AFP) is widely used in the diagnosis of HCC, but this biomarker has low specificity and may cause false positive or false ne...
Main Authors: | Jian Zhou, Yue Zhu, Yi Li, Kun Liu, Fei He, Sihuan Xu, Xin Li, Li Li, Junfang Hu, Yan Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | Infectious Agents and Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13027-021-00367-2 |
Similar Items
-
Serum Golgi protein-73 in combination with α-fetoprotein for diagnosing hepatocellular carcinoma in Egyptian patients
by: Mohamed M Makhlouf, et al.
Published: (2017-01-01) -
Evaluation of serum AFP (α-fetoprotein) level in HBsAg carrier patients for diagnosis of hepatocellular carcinoma
by: eskandar Hajiani, et al.
Published: (2006-06-01) -
Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review
by: Wen-Chi Chou, et al.
Published: (2018-02-01) -
The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia
by: Chyntia Olivia Maurine Jasirwan, et al.
Published: (2020-07-01) -
Prognostic value of α-fetoprotein response in treatment of hepatocellular carcinoma
by: JIA Jia
Published: (2013-08-01)